Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | PROOF 301: infigratinib in advanced CCA

Milind Javle • 30 Jun 2020
ESMO WCGIC 2020
Bile Duct Cancer Gastrointestinal Cancer Cisplatin Gemcitabine Infigratinib
PROOF 301

Milind Javle, MD, of MD Anderson Cancer Center, Houston, TX, outlines the rationale and trial design of PROOF 301 (NCT03773302), a Phase III study investigating first line infigratinib in cholangiocarcinoma (CCA) patients with FGFR2 gene fusions/translocations. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Milind Javle

2:31
Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusions
Milind Javle • 1 Jul 2020
1:15
Changes in the management of bilary tract cancer
Milind Javle • 30 Jun 2020

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals